Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Palmer JC et al. - ECE-2 expression is up-regulated, perhaps to minimize A beta accumulation, but this may also be a mechanism through which endothelin-1 production is increased and cerebral blood flow is reduced in AD. The findings suggest that endothelin-1 receptor antagonists, already licensed for treating other diseases, could be of benefit in AD therapies.

Related Articles

Does Diabetes Speed Up Memory Loss In Alzheimers Disease?
ScienceDaily, 10/28/09    Relevance Score: 70%%

Activated astrocytes: a therapeutic target in Alzheimer's disease?
Expert Review of Neurotherapeutics, 11/19/09    Relevance Score: 69%%

High Blood Pressure Likely in Alzheimers Offspring
MedLinePlus, 11/04/09    Relevance Score: 69%%

New Cause for Alzheimer Disease
ScienceDaily, 11/30/09    Relevance Score: 68%%

Protective Role For Copper In Alzheimers Disease
ScienceDaily, 10/14/09    Relevance Score: 68%%

Today in Neurologic Oncology...keeping you current

KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma
Clinical Cancer Research, 12/01/09

High-risk neuroblastoma: a therapy in evolution
Pediatric Hematology and Oncology, 11/30/09

Role of caspase 8 as a determinant in trail sensitivity of neuroblastoma cell lines
Pediatric Hematology and Oncology, 11/30/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address